PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YHX865. CME/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2024.

Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Professor Chloe Orkin has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies.
Grant/Research Support from Gilead Sciences, Inc. and ViiV Healthcare group of companies.
Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies.

Patient Advocate/Planner
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.

Patient Advocate/Planner
Donald Young has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.

Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
April W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.
Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.

Co-Chair/Planner
Tina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/BVW865. CME/CPD credit will be available until December 27, 2024.

Tools of the Trade: Prioritising Weight Management in People With Type 2 Diabetes – Sharpening Your Skills to Intensify Therapy and Engage in Shared Decision-Making

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Stefano Del Prato, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Amarin Corporation plc; Applied Therapeutics; EvaPharma; Lilly; The Menarini Group; Novo Nordisk A/S; Sanofi; and Sun Pharmaceutical Industries Ltd.
Speaker for Abbott; AstraZeneca; Berlin-Chemie AG; Boehringer Ingelheim International GmbH; Laboratori Guidotti S.p.a.; Lilly; The Menarini Group; Merck Sharp & Dohme; and Novo Nordisk A/S.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Go online to PeerView.com/DRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease. Upon completion of this activity, participants should be better able to: Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction; Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy; and Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.

Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
PD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.
Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.

Co-Chair/Planner
Jonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EGP865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2024.

Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Yelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/PZM865. CME/NCPD/AAPA credit will be available until November 26, 2024.

Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosures
W. Troy Donahoo, MD, FTOS, has no financial interests/relationships or affiliations in relation to this activity.

Amy J. Sheer, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Actors of Health Care Theatre have nothing to disclose.

Medical Directors
Angela McIntosh, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Margery Tamas, MPH, has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.

Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Roxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.
Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).
Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.
Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.

Co-Chair/Planner
Jeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.
Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.

Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.

Co-Chair/Planner
Shubham Pant, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKS865. CME/MOC/AAPA credit will be available until November 13, 2024.

Facing the Challenges of EoE Head On: A Game Plan for Diagnosis and Integrating Targeted Therapy Using a Team Approach

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Dan Atkins, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for The American Partnership for Eosinophilic Disorders (APFED) and CURED.

Patient/Planner
Valira Pietrangelo has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.